On the other hand, by screening for p15-inducing compounds, we have discovered the MEK inhibitor trametinib,45 which has recently been approved for the treatment of BRAF-mutated melanoma by the US Food and Drug Administration, EU, and others. The gene discussed is MAP2K7; the disease is melanoma.